Determination of risperidone and 9-hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders

Biomedical Chromatography

Volumn 23, Issue 9, 2009, Pages 929-934

  Jones, Tanya ^a   Van Breda, Karin ^b   Charles, Bruce ^c   Dean, Angela J ^c,d   McDermott, Brett M ^c,d   Norris, Ross ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b MATER HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Mater Child and Youth Mental Health Service   (Australia)

Author keywords

9 hydroxyrisperidone; Children; HPLC; Risperidone

Indexed keywords

PEDIATRICS;

9-HYDROXYRISPERIDONE; CHILD; CHILDREN AND ADOLESCENTS; HPLC; INTERNAL STANDARDS; MOBILE PHASIS; PRECISE METHOD; RAPID METHOD; RISPERIDONE; SIMPLE METHOD;

HEPTANE;

PALIPERIDONE; RISPERIDONE;

ACCURACY; ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG STRUCTURE; EMOTIONAL DISORDER; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE;

EID: 70349495531     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1204     Document Type: Article

References (28)

1. Aravagiri M and Marder SR. Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. Journal of Mass Spectrometry 2000; 35: 718-724.
2. Aravagiri M, Marder SR, Van Putten T and Midha KK. Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. Journal of Pharmaceutical Sciences 1993; 82: 447-449.
3. Aravagiri M, Marder SR, Wirshing D and Wirshing WC. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacophyschiatry 1998; 31: 102-109.
4. Aravagiri M, Marder SR, Nuechterlein KH and Gitlin MJ. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxy risperidone in schizophrenic patients treated chronically with various doses of risperidone. Therapeutic Drug Monitoring 2003; 25: 657-664.
5. Avenoso A, Facciolá G, Salemi M and Spina E. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. Journal of Chromatography B 2000; 746; 173-181.
6. Balant-Gorgia AE, Gex-Fabry M, Genet C and Balant LP. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Therapeutic Drug Monitoring 1999; 21: 105-115.
7. Castberg I and Spigset O. Serum concentrations of risperidone and 9- hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Therapeutic Drug Monitoring 2005; 27: 103-106.
8. Cheng-Shannon J, McGough JJ, Pataki C and McCracken JT. Second-generation antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2004; 14: 372-394.
9. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, VanBeijsterveldt L, VanPeer A and Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. Journal of Clinical Psychiatry 1994; 55(suppl.): 13-17.
10. Hiemke C. Clinical utility of drug measurement and pharmacokintics- therapeuticdrug monitoring in psychiatry. European Journal of Clinical Pharmacology 2008; 64: 159-166.
11. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA and Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 1998; 244: 685-693.
12. Jensen PS, Buitelaar J, Pandina GJ, Binder C and Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. European Child and Adolescent Psychiatry 2007; 16: 104-120.
13. Krouwer J and Rabinowitz R. How to improve estimates of imprecision. Clinical Chemistry 1984; 30: 290-292.
14. Le Moing JP, Edouard S and Levron JC. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 1993; 614: 333-339.
15. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC and Janssen PA. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 1988; 247: 661-670.
16. Leysen JE, Janssen PM, Megens AA and Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry 1994; 55(suppl.): 5-12.
17. LLerena A, Berecz R, Dorado P, de la Garza CS, Norberto MJ, Cáceres M and Gutiérrez JR. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. Journal of Chromatography B 2003; 783: 213-219.
18. Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Furukori H and Kaneko S. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia. Journal of Pharmaceutical and Biomedical Analysis 1999; 19: 595-601.
19. Olesen OV and Linnet K. Simplified high-performance liquid chromatographicmethod for determination of risperidone and 9- hydroxyrisperidone in serumfrom patients comedicated with other psychotropic drugs. Journal of Chromatography B 1997; 698: 209-216.
20. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE and Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Therapeutic Drug Monitoring 1998; 20: 380-384.
21. Price MC and Hoffman DW. Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography. Therapeutic Drug Monitoring 1997; 19: 333-337.
22. Raggi MA, Mandrioli R, Sabbioni C and Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Current Medicinal Chemistry 2004; 11: 279-296.
23. Remmerie BM, Sips LL, de Vries R, de Jong J, Schothuis AM, Hooijschuur EW and van de Merbel NC. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2003; 783: 461-472.
24. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N and Moller HJ. Risperidone plasma levels, clinical response and side-effects. European Archives of Psychiatry and Clinical Neuroscience 2005; 255: 261-268.
25. Schatz DS and Saria A. Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with coulometric detection. Pharmacology 2000; 60: 51-56.
26. Titier K, Déridet E, Cardone E, Abouelfath A and Moore N. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose. Journal of Chromatography B 2002; 772: 373-378.
27. Vermeulen A, Piotrovsky V and Ludwig AL. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. Journal of Pharmacokinetics and Pharmacodynamics 2007; 34: 183-206.
28. Woestenborghs R, Lorreyne W, Van Rompaey F and Heykants J. Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. Journal of Chromatography B 1992; 583: 223-230.